- Home
- RMAX vs ACHV Comparison
RMAX vs ACHV Comparison
Compare RMAX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- ACHV
- Stock Information
- Founded
- RMAX 1973
- ACHV N/A
- Country
- RMAX United States
- ACHV United States
- Employees
- RMAX N/A
- ACHV N/A
- Industry
- RMAX Real Estate
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RMAX Finance
- ACHV Health Care
- Exchange
- RMAX Nasdaq
- ACHV Nasdaq
- Market Cap
- RMAX 151.2M
- ACHV 167.6M
- IPO Year
- RMAX 2013
- ACHV N/A
- Fundamental
- Price
- RMAX $8.18
- ACHV $3.93
- Analyst Decision
- RMAX Hold
- ACHV Strong Buy
- Analyst Count
- RMAX 1
- ACHV 1
- Target Price
- RMAX $9.00
- ACHV $12.00
- AVG Volume (30 Days)
- RMAX 186.7K
- ACHV 689.7K
- Earning Date
- RMAX 10-30-2025
- ACHV 11-06-2025
- Dividend Yield
- RMAX N/A
- ACHV N/A
- EPS Growth
- RMAX N/A
- ACHV N/A
- EPS
- RMAX 0.62
- ACHV N/A
- Revenue
- RMAX $292,931,000.00
- ACHV N/A
- Revenue This Year
- RMAX N/A
- ACHV N/A
- Revenue Next Year
- RMAX $0.94
- ACHV N/A
- P/E Ratio
- RMAX $13.18
- ACHV N/A
- Revenue Growth
- RMAX N/A
- ACHV N/A
- 52 Week Low
- RMAX $6.90
- ACHV $1.84
- 52 Week High
- RMAX $14.31
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- RMAX 53.71
- ACHV 41.99
- Support Level
- RMAX $7.25
- ACHV $3.82
- Resistance Level
- RMAX $7.73
- ACHV $4.45
- Average True Range (ATR)
- RMAX 0.27
- ACHV 0.31
- MACD
- RMAX 0.07
- ACHV -0.14
- Stochastic Oscillator
- RMAX 87.56
- ACHV 13.60
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.